Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound with HMG-CoA reductase inhibitory activity, pharmaceutical composition and application thereof

A compound and reductase technology, applied in the field of biomedicine, can solve the problems of high price, drug resistance and efficacy, and achieve the effects of strong activity, overcoming drug resistance, and simple structure

Inactive Publication Date: 2021-05-04
NINGBO INST OF TECH ZHEJIANG UNIV ZHEJIANG
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Aiming at the problems of drug resistance, poor curative effect and high price of the blood lipid-lowering drugs in the prior art, the present invention provides a compound with HMG-CoA reductase inhibitory activity and the application of a pharmaceutical composition. The compound has a simple structure , It has strong inhibitory activity on HMG-CoA reductase and has a strong application prospect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound with HMG-CoA reductase inhibitory activity, pharmaceutical composition and application thereof
  • Compound with HMG-CoA reductase inhibitory activity, pharmaceutical composition and application thereof
  • Compound with HMG-CoA reductase inhibitory activity, pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034](1) Synthesis of the compound of formula II:

[0035]

[0036]In the formula, N is an integer of 1 to 3, and when N = 1, the structure of the compound is as shown in Formula II-1, and the structure of the compound is as shown in formula II-2, when n = 3 when n = 3 As shown in the following formula II-3:

[0037]

[0038]The compounds of formula II-1 are sesame phenol, commercialized, and purchased directly. The compounds of formula II-2 and formula II-3 were disclosed in conventional literature [Nippon Kagaku Kaishi (1977), (6), 925-7; JP 52133984], 1,2,4-benzene and 1, 2-dichloroethane or 1,3-dichloropropane reaction was prepared, and the specific reaction method was as follows.

[0039]Preparation of the compound of formula II-3: 1,2.4-phenyl phenol 12.6 g, 1,3-dichloropropane 11.3 g, sodium hydroxide 8.8 g and DMSO 63G reaction bottle, under stirring conditions, heated to 120 The reaction was reacted at -130 ° C for 6 hours, then cooled to room temperature, and then the pH of the concentr...

Embodiment 2

[0066]Example 2: COMPD1-9 inhibits human HMG-COA reductase activity test

[0067]NADPH, human HMG-CoA reductase, HMGRH detection kit and positive control simvastatin and dimethyl sulfoxide were purchased from US Sigma.

[0068]Specific experiments were carried out in accordance with the reagent specification: HMG-COA was 0.13 mm, HMGRH 1 μL, and the test sample was mixed with 50 mM pH = 7.5 tris-HCl buffer to 100 μL. After incubation at 37 ° C for 15 minutes, NADPH was added to 0.13 mm, and 10 minutes were detected continuously. The NADPH oxidation absorption value was measured at a wavelength of 340 nm by a spectrophotometer, and the activity of HMG-COA reductase activity was calculated according to the activity of the absorption value, and the desired sample concentration was calculated. The different sample experiment should be at least 6 times and do not add 2 times. Each unit enzyme activity is defined as the amount of enzyme required to catalyze 1 mmol NADPH oxidation per minute. Th...

Embodiment 3

[0072]Example 3: Lipcharin Experiment

[0073]The selection represents Compound COMPD 1, COMPD5, and COMPD9 for lipid-lowering tests in mice. Both the animal room, laboratory and experiments are carried out in GLP standards.

[0074]The drug is configured as follows:

[0075]Tyloxapol: A solution of 80 mg / mL was prepared by saline;

[0076]Simvastatin: A solution of 2 mg / ml was prepared by saline;

[0077]Try: A solution of 1 mg / ml, 2 mg / ml and 5 mg / ml of saline.

[0078]test:

[0079]Healthy male ICR mice, weight 18-22g, freely eating drinking water, randomly divided into blank group, model group, statin group and trial group. Each drug in the test group is divided into three dosage groups, a total of 12 groups, and 8 animals per group. Three doses of the test group were 5 mg / kg, 10 mg / kg and 25 mg / kg, and the dose of Tatin was 10 mg / kg. The administration is IP, the administration volume is 100 μL. The blank group was given a biological saline, the model group gave Tyloxapol, and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines, and particularly discloses a compound shown as a formula I and used for treating and / or preventing HMG-CoA reductase related diseases or pharmaceutically acceptable salt or ester of the compound. The invention also discloses a pharmaceutical composition containing the compound. In addition, the invention also provides an application of the compound as an HMG-CoA reductase inhibitor and in preparation of drugs for treating and / or preventing HMG-CoA reductase related diseases. The compound provided by the invention has relatively strong activity of inhibiting HMG-CoA reductase, the prepared medicine is expected to have a relatively good effect on treating and / or preventing dyslipidemia and atherosclerosis, and the compound is relatively simple in structure and relatively low in expected price. In addition, the structure of the compound provided by the invention is completely different from that of the existing statins, and the phenomenon of drug resistance to the existing statins can be overcome.

Description

Technical field[0001]The present invention relates to the field of biomedicine, and more particularly to compounds, pharmaceutical compositions, and applications having HMG-CoA reductase inhibitory activity.[0002]technical background[0003]Abnormal blood lipids, commonly known as high blood lipids, usually refer to serum cholesterol (Tc), low-density lipoprotein cholesterol (LDL-C) and / or triglyceride (Tg) level rises, is the most important risk factor for cardiovascular systems, and Its incidence is high and harmful. Blood lipid is an important factor in atherosclerosis (AS), atherosclerosis is the main cause of coronary heart disease, cerebral infarction, peripheral vascular disease. Lipid metabolic disorders are pathogen foundation of atherosclerosis. Its characteristics are due to incidental artery disease begins with the inner membrane, generally lipid and compound sugar accumulation, bleeding and thrombosis, and fibrous tissue proliferation and calcium calm, and The gradual t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D317/64C07D319/18C07D321/10A61K31/36A61K31/357A61P3/06A61P9/10
CPCA61P3/06A61P9/10C07D317/64C07D319/18C07D321/10
Inventor 金春华朱勤丰
Owner NINGBO INST OF TECH ZHEJIANG UNIV ZHEJIANG